Seelos Therapeutics Inc
NASDAQ:SEEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Seelos Therapeutics Inc
NASDAQ:SEEL
|
US |
Balance Sheet
Balance Sheet Decomposition
Seelos Therapeutics Inc
Seelos Therapeutics Inc
Balance Sheet
Seelos Therapeutics Inc
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
11
|
4
|
2
|
6
|
0
|
10
|
16
|
79
|
16
|
3
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
10
|
16
|
79
|
16
|
3
|
|
| Cash Equivalents |
11
|
4
|
2
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Accounts Receivables |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
1
|
1
|
2
|
0
|
0
|
1
|
2
|
5
|
7
|
2
|
|
| Total Current Assets |
13
|
6
|
4
|
7
|
0
|
11
|
17
|
83
|
23
|
5
|
|
| PP&E Net |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
15
N/A
|
8
-47%
|
5
-40%
|
7
+43%
|
0
-97%
|
11
+5 709%
|
17
+58%
|
84
+377%
|
23
-73%
|
5
-76%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
2
|
1
|
0
|
2
|
1
|
2
|
2
|
4
|
16
|
|
| Accrued Liabilities |
6
|
5
|
2
|
2
|
0
|
2
|
2
|
4
|
7
|
3
|
|
| Short-Term Debt |
0
|
9
|
7
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
2
|
0
|
2
|
1
|
12
|
14
|
|
| Other Current Liabilities |
0
|
0
|
2
|
0
|
0
|
8
|
1
|
2
|
2
|
6
|
|
| Total Current Liabilities |
7
|
16
|
11
|
2
|
5
|
11
|
7
|
8
|
25
|
39
|
|
| Long-Term Debt |
5
|
0
|
0
|
0
|
0
|
0
|
7
|
18
|
8
|
0
|
|
| Other Liabilities |
1
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
13
N/A
|
18
+38%
|
12
-31%
|
2
-81%
|
5
+110%
|
11
+127%
|
15
+34%
|
26
+75%
|
33
+27%
|
39
+17%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
290
|
309
|
316
|
316
|
5
|
56
|
75
|
141
|
215
|
253
|
|
| Additional Paid In Capital |
292
|
299
|
309
|
320
|
0
|
56
|
78
|
198
|
204
|
219
|
|
| Total Equity |
2
N/A
|
10
N/A
|
8
+24%
|
4
N/A
|
5
N/A
|
0
+100%
|
3
N/A
|
57
+2 129%
|
11
N/A
|
34
-216%
|
|
| Total Liabilities & Equity |
15
N/A
|
8
-47%
|
5
-40%
|
7
+43%
|
0
-97%
|
11
+5 709%
|
17
+58%
|
84
+377%
|
23
-73%
|
5
-76%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|